ALK and angioimmunoblastic T-cell lymphoma: Finally, 63 patients, including those with PTCL‐NOS (n = 30), AITL (n = 28), ALK‐negative ALCL (n = 4), and ALK‐positive ALCL (n = 1), participated in this study (Table 1).